Researchers from France's Gustave Roussy Institute designed EGFR mutation assays for the system, which they showed could be useful for testing in non-small cell lung cancer patients.
The test, which is currently for research use only, uses fluorescent multiplex PCR to co-amplify seven markers for analysis of the MSI-high phenotype.
The agreement with Mexico's agriculture department covers studies to evaluate molecular detection assays for bovine TB, as well as studies on zoonotic TB diagnosis.
PerkinElmer's subsidiary Wallac will now distribute the Amplidiag product line in Israel and in a number of countries in Africa.
While point-of-care molecular testing of patients with respiratory illness wasn't associated with lower antibiotic use, patients tested had shorter drug courses.
The firm is now launching the test in Europe, supported by results from a multicenter prospective study showing high sensitivity in detecting bladder cancer.
The company will still provide interpretation-only services, but by adding in-house testing it has dramatically increased its customer base.
The deal will help the Finnish diagnostics company expand its offerings of PCR-based gastrointestinal diagnostic tests.
Devyser recently launched NGS-based tests for cystic fibrosis and the BRCA genes and aims to launch others in oncology, reproductive health, and genetic disease.
The companies intend to bring companion diagnostics through US Food and Drug Administration clearance using ArcherDX's AMP chemistry and Illumina's MiSeqDx.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.